Stoke Therapeutics, Inc. (STOK)
Nasdaq: STOK · Pharmaceutical Preparations · Bedford, MA · filing with the SEC since 2014
Who owns Stoke Therapeutics, Inc.
As filed with the SECHolders of 5% or more
9
RTW Investments, LP holds 9.9% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13G/A filed May 15, 2026 says.
Directors and officers
15
report now, of 21 people on the record since 2019. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 9 named at left.
Holders of 5% or moreshare of the class, as filed
RTW Investments, LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.0001 per share · 9.99% in Feb 14, 2025
Fmr LLC
SCHEDULE 13G/A · filed Aug 6, 2026 · COMMON STOCK · 9.8% in Feb 5, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Oct 17, 2025 · Common Stock · 5.8% in Apr 16, 2025
Redmile Group, LLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.0001 par value per share · 8% in Aug 14, 2025
Lynx1 Capital Management LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.0001 par value per share · 8.1% in May 18, 2026
Morgan Stanley
SCHEDULE 13G/A · filed Feb 3, 2025 · Common Stock
Baker Bros. Advisors LP
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.0001 per share
Bvf Partners L P/il
SCHEDULE 13G · filed Sep 30, 2026 · Common Stock, $0.0001 par value per share
Wellington Management Group LLP
SCHEDULE 13G · filed May 15, 2026 · Common Stock
Toronto Dominion Bank
SCHEDULE 13G/A · filed Aug 12, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 5.4% in May 15, 2026
BlackRock Portfolio Management LLC
SCHEDULE 13G/A · filed Jul 15, 2025 · Common Stock · reported falling below 5%, from 5.1% in Apr 15, 2025
Montrago Trustees Ltd
SCHEDULE 13D/A · filed Aug 26, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 6% in Jun 23, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
Cowen Financial Products LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 5.8% in Jul 29, 2025
What STOK reports owning in othersstakes of 5% or more, and other ties
Stoke Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
81sales
0purchases
48sales on a scheduled plan
8people selling
$9.0Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 4, 2025 to Nov 4, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 4, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window8 of 31 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Krainer Adrian R. | director | 5 | $3.9M | 5 | 0 | $0 |
| Ticho Barry | CHIEF MEDICAL OFFICER | 28 | $1.9M | 22 | 0 | $0 |
| Kaye Edward M. Md | CEO | 14 | $1.4M | 8 | 0 | $0 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC | 22 | $1.3M | 11 | 0 | $0 |
| Tzianabos Arthur | Interim Executive Chair | 1 | $200,000 | 1 | 0 | $0 |
| Leggett Thomas | Chief Financial Officer | 5 | $100,000 | 0 | 0 | $0 |
| Hoitt Jason | Chief Patient Officer | 5 | $100,000 | 0 | 0 | $0 |
| Levin Arthur A | director | 1 | $0 | 1 | 0 | $0 |